2010工艺过程中的颗粒论坛会上的三位报告者将在2011年1月21日于（美国）马里兰州的巴尔的摩举行的IFPAC (工艺过程分析技术国际论坛)上作报告。Johnson & Johnson的Steve Mehrman和Merck & Co. 的James Butz被排在周五上午的“颗粒特征分析–超声光谱”IFPAC 的第五分会作报告。Bristol-Myers Squibb的Kevin Macias将在周五上午的“药品开发与生产的控制战略”第七分会中作报告。 Continue reading
Three speakers from the 2010 In-Process Particle Forum will present at IFPAC [International Forum Process Analytical Technology] on January 21, 2011 in Baltimore, MD. Steve Mehrman of Johnson & Johnson and James Butz of Merck & Co. are scheduled to present during the Particle Characterization/Analysis-Ultrasound Spectroscopy Friday AM V session at IFPAC. Kevin Macias of Bristol-Myers Squibb will present during the Control Strategies for Drug Product Development and Manufacturing Friday AM VII session. Continue reading
- 包括工艺放大的用于Drown-out 结晶过程的工艺模拟手段， Eleftherios Kougoulos – Pfizer
- 用PAT (工艺过程分析技术)定性分析快速结晶工艺过程, Barbara Wood – University College Dublin
- 结晶工艺自动化平台: 集成硬件、软件、和PAT来促进结晶工艺过程的开发， Amanda Rogers – Bristol-Myers Squibb
- 应用PAT来定义设计空间从而实现结晶工艺过程的控制战略, George Zhou – Merck & Co.
- 在一个工业化半釜式糖结晶釜中实时监测晶体成核和增长速率, Terry Redman – METTLER TOLEDO
- 结合工艺过程分析技术的结晶过程放大–确保从R&D 实验室到生产厂的成功, Terry Redman – METTLER TOLEDO
- PAT在设计和优化塞流结晶系统中的应用, University College Dublin
- 在2,6-Diamino-3,5-Dinitropyrazine-1-Oxide (LLM-105) 重结晶中应用原位技术, Andrew G. Pearsall – Naval Surface Warfare Center
- 建立一个从起始晶种分布预测过饱和度和晶体大小的结晶过程模型的成功与挑战, James Vernille – Bristol-Myers Squibb
While reviewing the technical program for the upcoming 2010 American Institute of Chemical Engineers (AIChE) Annual Meeting, I noticed several papers of interest to those of us who work in crystallization: Continue reading
I am excited to be chairing the upcoming In Process Particle Forum focused on Liquid and Solid Dosage Formulations on September 15 in Woodbridge, NJ. This will be the third year in a row that METTLER TOLEDO has brought together expert users of FBRM and PVM to present their cutting edge research to a group of their peers. This year, we have the best agenda yet with four industry papers from:
- Bristol-Myers Squibb
- Johnson and Johnson
A few months ago, I came across two letters in Chemical & Engineering News that I would like to bring to your attention. Both letters relate to ensuring the safety of chemical processes.
The first, from Tom Vickery and colleagues at Merck, made the point that a recently published procedure (for preparation of 2-bromo-3-methylbutenal) presents a safety issue with dramatic consequences for scale-up:
The on-demand version of the Reducing Time to Manufacturing Using Real-time In Situ FTIR Analytics as a Process Analytical Technology (PAT) Tool webinar that I presented on January 20 is now available.
During this on-demand webinar, I review case studies from the pharmaceutical industry to show how real-time mid-infrared (mid-IR) analytics provide critical information that results in shorter process development timelines, including:
- Intermediate detection during an indazole alkylation and scale-up – Pfizer
- Hazardous gas detection during tetrazole synthesis – Merck
- Monitoring a Grignard reaction at the multikilogram scale – Bristol-Myers Squibb
- Scale-up involving a sensitive enolate – Johnson and Johnson (J&J)
If you have any questions or would like to discuss this further, then please contact me.